Jim HealyGeneral Partner at Sofinnova Ventures
Jim joined Sofinnova in 2000 as a General Partner. He focuses on funding clinical stage private and publicly traded bio-pharmaceutical companies. He has financed or served on the board of ten companies which received drug approvals from either FDA or EMA, seventeen companies which completed initial public offerings, and eleven companies which were acquired as private or as public companies. Jim currently represents Sofinnova on the board of directors of Ascendis (ASND), Coherus (CHRS), Edge (EDGE), Natera (NTRA), Obseva (OBSV), Nucana (NCNA), Iterum (ITRM) and Y-mAbs (YMAB).